FAM19A4 Antibody

1. Hypermethylation of FAM19A4/miR124-2 in the self-sample was tested in a quantitative methylation specific PCR and compared between lesions caused by HPV16/18 and other hrHPV genotypes. There were no differences in the percentages of positive FAM19A4/miR124-2 methylation assays between lesions caused by HPV16/18 (73.8% in CIN3+) or other hrHPV genotypes (66.7% in CIN3+) (p=0.538). PMID: 30219239
2. With a similarly good clinical performance in both sample types, combined FAM19A4 methylation analysis and HPV16/18 genotyping provides a feasible triage strategy for hrHPV-positive women, with direct applicability on self-samples PMID: 27415009
3. FAM19A4/mir124-2 methylation analysis performs equally well in HPV-positive lavage- and brush self-samples to identify women with CIN3+. In combination with HPV16/18 genotyping, significantly higher CIN3+ sensitivities are obtained, at decreased specificity. PMID: 26921784
4. FAM19A4 is a novel ligand of formyl peptide receptor 1. PMID: 25109685
5. among high risk HPV-positive women from an outpatient population aged >/= 30 years, methylation analysis of FAM19A4 is an attractive marker for the identification of women with high-grade cervical intraepithelial neoplasia and cervical cancer PMID: 26317579
6. High methylation of FAM19A4 is associated with cervical carcinomas. PMID: 25281488

Show More

Hide All

HGNC: 21591

OMIM: 617498

KEGG: hsa:151647

STRING: 9606.ENSP00000295569

UniGene: Hs.187873